Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Phase II trial show nilotinib achieves remission Philadelphia-positive acute lymphocytic leukaemia

Oliver Ottmann • 5 Dec 2014
ASH 2014
Acute Lymphoblastic Leukemia Nilotinib

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Oliver Ottmann (Goethe-University Hospital, Frankfurt, Germany) discusses a Trial of the European Working Group for Adult ALL (EWALL-PH-02), which evaluated nilotinib and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia chromosome/BCR-ABL1-positive acute lymphoblastic leukaemia.

More from Oliver Ottmann

3:38
Impact of increased drug availability on acute leukemia
Oliver Ottmann • 3 Jul 2020
3:24
Molecular profiling to determine treatment for ALL and AML
Oliver Ottmann • 3 Jul 2020
3:07
How age as a prognostic factor affects treatment options for ALL
Oliver Ottmann • 3 Jun 2020
5:23
Treatment options for Ph+ ALL
Oliver Ottmann • 3 Jul 2020

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals